Nomura Holdings’s AbCellera Biologics ABCL Stock Holding History

Nomura Holdings’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,400	Closed	-$116K	–	1330
2023 Q1	$116K	Buy	+15,400	New	+$140K	﹤0.01%	1275

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Nomura Holdings's ABCL Position: Q2 2023 in Review

Nomura Holdings sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 15,400 shares — an estimated $116K sold.

Nomura Holdings first reported a position in ABCL in Q1 2023 and held it in 1 quarter. The position peaked at $116K in Q1 2023. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Nomura Holdings reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Nomura Holdings sold 15,400 AbCellera Biologics shares in Q2 2023, an estimated $116K.
Nomura Holdings first reported a position in AbCellera Biologics in Q1 2023 and held it in 1 quarter.
Nomura Holdings's AbCellera Biologics position peaked at $116K in Q1 2023.
169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Nomura Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.